Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Malignant pleural effusion (MPE) is associated with substantial symptom burden and limited survival. Recent advances in pleural interventions, molecular diagnostics and prognostic tools are challenging traditional approaches to management. This review summarizes recent developments and considers how these may support more personalised care. RECENT FINDINGS: Indwelling pleural catheters (IPCs) and talc pleurodesis remain the principal definitive treatment strategies, with increasing evidence supporting individualized selection according to lung expandability, prognosis, treatment burden and patient preference. Accelerated diagnostic and therapeutic pathways may reduce repeated procedures. The RED score may help estimate time to further pleural intervention, pending broader validation and evaluation of clinical utility. Patient-reported outcomes and treatment burden are increasingly recognized as important measures of treatment success. SUMMARY: MPE management should integrate tumour biology, pleural physiology, prognosis and patient preferences. Emerging diagnostic, prognostic and technological advances may further enable personalized, patient-centred care.
No takes yet. Share an insight, caveat, or question.
Shiham et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: